COGT
Cogent Biosciences·NASDAQ
--
--(--)
--
--(--)
6.40 / 10
Outperform
Analyst sentiment is bullish with H.C. Wainwright lifting its target to $52 and Wedbush also rating the stock positively. Fund-flow data show consistent inflows across all sizes (extra-large inflow ratio 0.53), supporting the bullish view. However, the current price decline (-7.78%) creates a mismatch with expectations. Together, analyst conviction and positive capital movement offset short-term technical weakness, pointing to potential recovery if momentum turns.
Fund Flow Rating
Analyst RatingStrong Buy
Wall Street Opinions
Strong Buy
Strong Buy
50%
Buy
50%
Hold
0%
Sell
0%
Strong Sell
0%
Date2026-01-21
InstitutionWedbush
Times predicted1
Historical Win Rate0.0%
Is money flowing into or out of COGT?
- COGT holds a Bearish analyst rating, with 50% of experts assigning a Strong Buy grade. Factoring in net Inflows from order flow data, the comprehensive Sentiment Score stands at 6.40/10 (Outperform).
